Journal for Immunotherapy of Cancer

Article	Citations
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers	489
Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma	213
217 Cytotoxicity of nicotinamide enhanced natural killer cells GDA201 is based on metabolic modulation as demonstrated by artificial intelligence assisted analysis of NK cell transcriptome and metabol	175
38 Spatial immune profiling of human glioblastoma tissue reveals the presence of aggregated lymphoid niches in the tumor microenvironment	172
Arginase-2-specific cytotoxic T cells specifically recognize functional regulatory T cells	166
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap	165
Commentary on oncolytic viruses: past, present, and future	148
Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models	145
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses	137
Evaluation of immune checkpoint inhibitor efficacy for solid tumors withCD274(PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide	136
Response to "NLRC5germline variants and their potential role in eliciting an immune response in patients with cancer treated with immune checkpoint inhibitors" by Xiang-Yu Meng	132
Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy	129
Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design	129
Correction: Two roads for oncolytic immunotherapy development	126
Correction: Treg-selective IL-2 starvation synergizes with CD40 activation to sustain durable responses in lymphoma models	126
Correction: PP4 inhibition sensitizes ovarian cancer to NK cell-mediated cytotoxicity via STAT1 activation and inflammatory signaling	126
Correction: A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer	119
B7-H3 CAR-T cell therapy combined with irradiation is effective in targeting bulk and radiation-resistant chordoma cancer cells	118
TIPE2deletion improves the therapeutic potential of adoptively transferred NK cells	115
24 Nivolumab serum concentration in metastatic melanoma patients could be related to anti-tumor activity gene and outcome	115
Correction: Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer	114
Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	113
Modulation of lactate-lysosome axis in dendritic cells by clotrimazole potentiates antitumor immunity	110
Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors	110
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade	106

Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis	102
GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma	101
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders	99
First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphoma	98
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype	98
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes	96
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images	96
Hybrid epithelial-mesenchymal status of lung cancer dictates metastatic success through differential interaction with NK cells	96
Biomarkers for response to TIL therapy: a comprehensive review	94
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival	91
Single-cell analysis reveals clonally expanded tumor-associated CD57+CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade	90
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunothera	89
Human MAIT cells are devoid of alloreactive potential: prompting their use as universal cells for adoptive immune therapy	89
Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments	88
Localization and density of tertiary lymphoid structures associate with molecular subtype and clinical outcome in colorectal cancer liver metastases	87
T-cell tolerant fraction as a predictor of immune-related adverse events	86
Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer	86
Genomic and transcriptomic characterization of heterogeneous immune subgroups of microsatellite instability-high colorectal cancers	85
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors	84
Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression	82
iRECIST and atypical patterns of response to immuno-oncology drugs	82
Targeting of GSDMD sensitizes HCC to anti-PD-1 by activating cGAS pathway and downregulating PD-L1 expression	82
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study	81
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release	80
Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study	79
Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy	79
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion	79
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision	79
Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck	79
Macrophage-inherited exosome excise tumor immunosuppression to expedite immune-activated ferroptosis	78
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study	78
Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy	76
Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer	74
370 Time course of treatment-related adverse events (TRAEs) during dostarlimab therapy in the GARNET trial	73
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer	73
Modulating lipid metabolism improves tumor immunotherapy	73
17 Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients	72
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy	71
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies	69
77 Prevalence of secondary immunotherapeutic targets in the absence of established immune biomarkers in solid tumors	69
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis	68
SIGLEC11 promotes M2 macrophage polarization through AKT–mTOR signaling and facilitates the progression of gastric cancer	67
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation	67
Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment	66
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia	65
Poor clinical outcomes and immunoevasive contexture in CD161+CD8+T cells barren human pancreatic cancer	65
Irreversible electroporation synergizes with oncolytic virus enhances the infiltration of cytotoxic T lymphocytes in the tumor immune microenvironment: a leap from focal therapy to immunotherapy for p	65
Sulforaphane activates CD8+T cells antitumor response through IL-12RB2/MMP3/FasL-induced MDSCs apoptosis’	64
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs	64
Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis	64

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy	63
PD-L1 gene amplification and focality: relationship with protein expression	63
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma	62
Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study	62
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy	62
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+T cell cytotoxicity over BEMPEG+RT	62
Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition	62
Apoptosis: aJanus bifronsin T-cell immunotherapy	62
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species	61
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers	60
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer	59
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy	59
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma	59
Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity	59
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC	59
Correction: Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy	58
11 Molecular characterization of naturally occurring colorectal and breast cancer in non-human primates to model human immunotherapeutic agents	58
Correction: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	57
Correction: Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages	57
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes	57
Correction: Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer	57
Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells	56
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16	56
Vaccination generates functional progenitor tumor-specific CD8 T cells and long-term tumor control	56
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors	56
Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression	55
Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth	55
Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination	55
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer	55
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function	55
In memoriam: Soldano Ferrone, MD, PhD (1940–2023)	55
RANKL blockade inhibits cancer growth through reversing the tolerogenic profile of tumor-infiltrating (plasmacytoid) dendritic cells	54
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies	54
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial	54
Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechalle	54
PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8+T cell-dependent antitumor immunity and abscopal effect after local irradiation	54
Addendum 1:Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0	54
Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study	54
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer	53
TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation	53
Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer	53
Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer	53
TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion	53
Targeting cancer testis antigens in synovial sarcoma	53
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types	52
Accumulation of T-cell-suppressive PD-L1highextracellular vesicles is associated with GvHD and might impact GvL efficacy	52
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D	52
Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models	51
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes	51
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch	51
Novel post-translational modification learning signature reveals B4GALT2 as an immune exclusion regulator in lung adenocarcinoma	51
Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity	51
286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC)	50
Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report	50
Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade	50
Gut microbiome-depleting antibiotic regimens are not tolerated by all mouse strains: learn from (our) bitter experience	50
Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses	50
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders	49
Guidelines for immunological analyses following focused ultrasound treatment	49
Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies	49
Letter to the Editor from Colleet al	49
Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma	49
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer	49
Id-neoantigen vaccine induces therapeutic CD8+T cells against multiple myeloma: H chain-loss escapees cause FLC MM	49
Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist	49
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression	48
20 Tumor-informed liquid biopsy monitoring of evolving therapeutic resistance mechanisms in head and neck squamous cell carcinoma patients receiving anti-PD-1 therapy	48
Integrated single-cell transcriptome and TCR profiles of hepatocellular carcinoma highlight the convergence on interferon signaling during immunotherapy	48
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma	48
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity	48
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer	48
Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)	48
Response to: Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Chhedaet al	48
Reinforcing cancer immunotherapy with engineered porous hollow mycobacterium tuberculosis loaded with tumor neoantigens	47
Correction: Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel	47
Correction: Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?	47
36 Digital Whole Slide Image (WSI) scoring is equivalent to microscope glass slide scoring for evaluation of programmed death-ligand 1 (PD-L1) expression across multiple tumor indications	47
Correction: Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers	47
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling	46
Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy	46

Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer	46
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors	46
Neoantigens as potential vaccines in hepatocellular carcinoma	46
JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy	45
TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+T cell and XCR1+dendritic cell spatial co-localization	45
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers	45
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma	45
Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses	45
Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade	45
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer	45
The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer	45
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors	45
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer	45
Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy	44
Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma	44
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy	44
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies	44
Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial	44
Correction: Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events	44
Peptide: MHC-based DNA vaccination strategy to activate natural killer cells by targeting killer cell immunoglobulin-like receptors	44
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)	44
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome	43
Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG	43
322 Melanoma-intrinsic hypoxia-inducible factor-1α results in diminished T cell accumulation within the tumor microenvironment	43
Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors	43
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex	43
Correction: Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy	43
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity	43
19 Exome-scale liquid biopsy characterization of emerging immune resistance mechanisms in treatment-resistant GIST	43
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma	43
Correction: Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody	42
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy	42
PLS-α-GalCer: a novel targeted glycolipid therapy for solid tumors	42
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models	42
Spatial immune remodeling of the liver metastases: discovering the path to antimetastatic therapy	42
45 AI-assisted whole-body assessment of immunotherapy response using [18F]F-AraG, a PET agent for activated T cells	42
52 Characterization of the tumor microenvironment in melanoma using Multiplexed Ion Beam Imaging (MIBI)	42
291 Dual-specific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 restore anti-tumor immunity	42
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors	42
Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a ph	41
Natural killer cells are required for the recruitment of CD8+ T cells and the efficacy of immune checkpoint blockade in melanoma brain metastases	41
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma	41
Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer	41
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation	41
Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization	41
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial	41
Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation	41
Network-based screening identifies sitagliptin as an antitumor drug targeting dendritic cells	41
Peritumoral administration of immunomodulatory antibodies as a triple combination suppresses skin tumor growth without systemic toxicity	41
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients withBRAFV600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)	41
212 Tumor adjacent cytokine factories for eradication of ovarian cancer tumor burden in mice through cytotoxic T-cell activation with safe and predictable dosing in non-human primates	41
Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins	40
Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy	40
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells	40
292 Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in solid tumors	40
Correction: MRI techniques for immunotherapy monitoring	40
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab	40
64 A cloning and expression system of the neoantigen-specific TCRs from tumor-infiltrating lymphocytes by single-cell sequencing of paired TCRα and TCRβ chains	40
DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma	40
Correction: Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition	40
Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis	39
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C	39
Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR	39
Body mass index and type 2 diabetes mellitus as metabolic determinants of immune checkpoint inhibitors response in melanoma	39
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy	39
Uncoupled biological and chronological aging of neutrophils in cancer promotes tumor progression	39
Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer	39
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma	39
No detrimental association between antibiotic use and immune checkpoint inhibitor therapy: an observational cohort study comparing patients with ICI-treated and TKI-treated melanoma and NSCLC	38
318 Enforced tumor specific MHC-I heterogeneity in triple negative breast cancer drives immunotherapy resistance	38
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types	38
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas	38
Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’	38
NK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases	38
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatment	38
Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective study	38
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive	38
Novel treatments for novel side effects: a case report and review of baricitinib use in the treatment of chronic inflammatory demyelinating polyneuropathy caused by immune checkpoint inhibitor use	38
Letter to the editor: transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study	38
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817	38
Correction: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer	38
Intratumoral STING agonist reverses immune evasion in PD-(L)1-refractory Merkel cell carcinoma: mechanistic insights from detailed biomarker analyses	37
Vaccines for immunoprevention of DNA mismatch repair deficient cancers	37
Multiomics profiling reveals the benefits of gamma-delta (γδ) T lymphocytes for improving the tumor microenvironment, immunotherapy efficacy and prognosis in cervical cancer	37
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma	37
Targeting B7-H3 inhibition-induced activation of fatty acid synthesis boosts anti-B7-H3 immunotherapy in triple-negative breast cancer	37
Loss of YTHDF1 in gastric tumors restores sensitivity to antitumor immunity by recruiting mature dendritic cells	37
Tryptophan potentiates CD8+T cells against cancer cells by TRIP12 tryptophanylation and surface PD-1 downregulation	37
In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade	37
Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies	37
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma	37
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies	37
A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma	37
Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma	36
Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?	36